← Back
NeuroTrials.ai
Neurology Clinical Trial Database

AcT

Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial

Year of Publication: 2022

Authors: Menon BK, Buck BH, Singh N, ..., Field TS

Journal: The Lancet

Citation: Lancet. 2022 Jul 16-22;400(10347):161-169.

Link: https://doi.org/10.1016/S0140-6736(22)01054-6


Clinical Question

Is intravenous tenecteplase (0.25 mg/kg) non-inferior to alteplase (0.9 mg/kg) in patients with acute ischaemic stroke presenting within 4.5 h of symptom onset?

Bottom Line

Intravenous tenecteplase 0.25 mg/kg given as a single bolus is non-inferior to alteplase 0.9 mg/kg (bolus + infusion) for 90–120 day functional outcome (mRS 0–1) in acute ischaemic stroke patients eligible for thrombolysis within 4.5 h, with similar safety. Tenecteplase is a reasonable alternative to alteplase as standard-of-care thrombolytic.

Major Points

  • First phase 3 RCT to demonstrate non-inferiority of tenecteplase 0.25 mg/kg vs alteplase 0.9 mg/kg for 90–120 day mRS 0–1 in acute ischaemic stroke within 4.5 h.
  • Primary outcome (mRS 0–1 at 90–120 days): 36.9% tenecteplase vs 34.8% alteplase; unadjusted risk difference 2.1% (95% CI –2.6 to 6.9), meeting the prespecified –5% non-inferiority threshold.
  • Safety profile comparable: 24 h symptomatic intracerebral haemorrhage 3.4% vs 3.2%; 90-day mortality 15.3% vs 15.4%.
  • Pragmatic, registry-linked, multicentre design across 22 Canadian primary and comprehensive stroke centres enhances generalisability.
  • Single-bolus administration of tenecteplase offers workflow advantages, especially for drip-and-ship and endovascular thrombectomy candidates.

Design

Study Type: Pragmatic, multicentre, open-label, parallel-group, registry-linked, randomised, controlled, non-inferiority trial with blinded outcome assessment

Randomization: 1

Blinding: Open-label treatment allocation; blinded (central, masked) outcome assessment via standardised telephone interviews

Allocation: 1:1 using a previously validated minimal sufficient balance algorithm to balance allocation by site; fully concealed via secure real-time web-based server

Enrollment Period: Dec 10, 2019 to Jan 25, 2022

Follow-up Duration: Up to 120 days after randomisation (primary outcome at 90–120 days)

Centers: 22

Countries: Canada

Sample Size: 1600

Analyzed: 1577

Analysis: Intention-to-treat (ITT) for primary outcome (all randomised who did not withdraw consent); per-protocol as secondary exploratory; safety in all treated patients

Power Calculation: Assuming 35% mRS 0–1 in alteplase and 38% in tenecteplase, one-sided non-inferiority margin of 5% and one-sided α of 0.025, total sample of 1600 ensured ≥90% power with up to 5% loss to follow-up

Registration: ClinicalTrials.gov NCT03889249


Inclusion Criteria

  • Age ≥18 years
  • Diagnosis of ischaemic stroke causing disabling neurological deficit
  • Presentation within 4.5 h of symptom onset
  • Eligible for intravenous thrombolysis per Canadian Stroke Best Practice Recommendations (CSBPR 2018)
  • Patients also eligible for endovascular thrombectomy were eligible for enrolment

Exclusion Criteria

  • Standard contraindications to intravenous thrombolysis per CSBPR (e.g., active haemorrhage or condition increasing risk of major haemorrhage after alteplase)
  • Pregnancy (per medical history/exam) without consultation with an expert stroke physician

Baseline Characteristics

CharacteristicTenecteplase (n=806)Alteplase (n=771)
Median age, years (IQR)74 (63–83)73 (62–83)
Female, n (%)382 (47.4%)373 (48.4%)
Male, n (%)424 (52.6%)398 (51.6%)

Arms

FieldTenecteplaseControl
N806771
InterventionIntravenous tenecteplase as a one-time decile-weight-tiered bolus of 0.25 mg/kg (maximum 25 mg)Intravenous alteplase total dose 0.9 mg/kg (maximum 90 mg), given as 0.09 mg/kg bolus followed by 60 min infusion of remaining 0.81 mg/kg
DurationSingle bolusBolus + 60 min infusion

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Proportion of patients with a modified Rankin Scale (mRS) score of 0–1 (intention-to-treat)Primary34.8% (266/765) alteplase36.9% (296/802) tenecteplaseUnadjusted risk difference 2.1% (favoring tenecteplase); non-inferiority met (lower 95% CI > –5%)
90–120 day mRS score of 0–2Secondary
Actual 90–120 day mRS score (ordinal)Secondary
Return to baseline function at 90 daysSecondary
90–120 day EQ-VAS and EQ-5D-5LSecondary
Door-to-needle timeSecondary
Proportion of patients given endovascular therapySecondary
Recanalisation status at first angiographic acquisition (extended TICI and revised AOL) in patients taken for endovascular therapySecondary
Baseline CT to arterial puncture time in patients undergoing endovascular therapySecondary
Cognition via brief online cognitive assessment (to be reported separately)Secondary
Length of hospital stay (post-hoc)Secondary
Discharge destinationSecondary
24 h symptomatic intracerebral haemorrhage: 3.4% (27/800) tenecteplase vs 3.2% (24/763) alteplaseSafety
90-day all-cause mortality: 15.3% (122/796) tenecteplase vs 15.4% (117/763) alteplaseSafety
Orolingual angio-oedema within 24 h of thrombolysis (data not detailed in abstract)Safety
Extracranial bleeding requiring blood transfusion within 24 h (data not detailed in abstract)Safety
24h Symptomatic ICH - TenecteplaseAdverse27/800 (3.4%)
24h Symptomatic ICH - AlteplaseAdverse24/763 (3.2%)
90-day Mortality - TenecteplaseAdverse122/796 (15.3%)
90-day Mortality - AlteplaseAdverse117/763 (15.4%)

Subgroup Analysis

Prespecified subgroups assessed for heterogeneity of treatment effect: age (<80 vs ≥80), sex, baseline NIHSS (<8 vs 8–15 vs >15), symptom onset-to-needle time (≤180 vs >180 min), large vessel occlusion (yes/no including ICA, M1 MCA, or functional M1 MCA on CTA), type of enrolling centre (comprehensive vs primary stroke centre), and source registry (OPTIMISE vs QuiCR). All exploratory; per the trial, results were consistent across subgroups.


Criticisms

  • Open-label design (treatment allocation not masked to clinicians or patients), although outcome assessment was blinded
  • Single-country (Canada) enrolment may limit generalisability to other health systems
  • Race and ethnicity data not collected
  • Non-inferiority margin of 5% on absolute risk difference is generous and could mask a clinically meaningful inferiority

Funding

Canadian Institutes of Health Research; Alberta Strategy for Patient Oriented Research Support Unit. Funders had no role in study design, data collection, analysis, interpretation, or report writing.

Based on: AcT (The Lancet, 2022)

Authors: Menon BK, Buck BH, Singh N, ..., Field TS

Citation: Lancet. 2022 Jul 16-22;400(10347):161-169.

Content summarized and formatted by NeuroTrials.ai.